title: Normal cortical energy metabolism in migrainous stroke: A 31P-MR spectroscopy study.
abstract: OBJECTIVE
  Previous (31)P-magnetic resonance spectroscopy ((31)P-MRS) studies have shown that cerebral cortical energy metabolism is abnormal in migraine and that cortical energy reserves decrease with increasing severity and duration of aura. Migrainous infarction is a rare complication of migraine with aura, and its pathophysiology is poorly understood. We used (31)P-MRS to determine whether migrainous stroke shows similar interictal abnormalities in cortical energy metabolism as severe, prolonged aura.
  
  
  METHODS
  We used (31)P-MRS to study patients with a diagnosis of either migrainous infarction or migraine with persistent aura without infarction (aura duration >7 days) according to International Headache Society criteria. We compared clinical presentation and metabolite ratios between patient groups. We also studied healthy controls with no history of migraine.
  
  
  RESULTS
  Patients with persistent aura without infarction had lower phosphocreatine-phosphate (PCr/Pi) ratios (mean+/-SD, 1.61+/-0.10) compared with controls (1.94+/-0.35, P=0.011) and with patients with migrainous stroke (1.96+/-0.16, P<0.0001). These differences were present in cortical tissue only. In migrainous stroke patients, the metabolite ratios did not differ significantly from those of controls without migraine.
  
  
  CONCLUSIONS
  The differences in cortical energy reserves between patients with migrainous stroke and in those with migraine with persistent aura suggest that the pathomechanisms of these conditions differ and that migrainous infarction does not simply represent a particularly severe form of migrainous aura. This finding supports the revised International Headache Society criteria, which now distinguish between migrainous infarction and migraine with persistent aura without infarction.
authors.affiliation: Stroke Prevention Research Unit, University Department of Clinical Neurology, John Radcliffe Hospital, Oxford OX2 9DU, UK. ursula.schulz@clneuro.ox.ac.uk
authors.forename: Ursula G
authors.initials: UG
authors.lastname: Schulz
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Blamire
authors.forename: Paul
authors.initials: P
authors.lastname: Davies
authors.forename: Peter
authors.initials: P
authors.lastname: Styles
authors.forename: Peter M
authors.initials: PM
authors.lastname: Rothwell
mesh_terms: D015415:Biomarkers / Q000032:analysis / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism* / Q000503:physiopathology; D003937:Diagnosis, Differential; D004734:Energy Metabolism / Q000502:physiology*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008881:Migraine Disorders / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism*; D020325:Migraine with Aura / Q000175:diagnosis / Q000378:metabolism; D010710:Phosphates / Q000032:analysis / Q000378:metabolism; D010725:Phosphocreatine / Q000032:analysis / Q000378:metabolism; D010761:Phosphorus Radioisotopes; D011237:Predictive Value of Tests; D020521:Stroke / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D010725:Phosphocreatine